Enliven Therapeutics, Inc. ELVN
44.83 USD +0.20 (+0.45%)
At closeNov 3, 2026, 4:01 PM EST
44.83 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
44.64 Day range 45.90
14.79 52-week range 62.32
- YTD
- +191.10%
- 1 year
- +124.15%
News
benzinga.com HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $73 HC Wainwright & Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $65 to $73.
prnewswire.com Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year Accomplished biopharmaceutical executive with extensive experience in corporate strategy, finance and commercial readiness Enliven continues preparation for late-stage development and…
prnewswire.com Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia Enliven remains on track to initiate ENABLE-2 before year-end 2026 BURLINGAME, Calif., Oct. 6, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a…
defenseworld.net Enliven Therapeutics (NASDAQ:ELVN) Stock Falls 4.5% Following Insider Selling Enliven Therapeutics, Inc. (NASDAQ: ELVN - Get Free Report) shares fell 4.5% during mid-day trading on Tuesday following insider selling activity. The company traded as low as $43.20 and last traded…
benzinga.com This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Analysts initiated coverage: VYLR Outperform/$85, LBRX Buy/$68, ELVN Overweight/$70, SAIL Sector Weight, and AVLN Outperform/$60.
benzinga.com Morgan Stanley Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $70 Morgan Stanley analyst Sean Laaman initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Overweight rating and announces Price Target of $70.
benzinga.com JP Morgan Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $75 JP Morgan analyst Priyanka Grover initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Overweight rating and announces Price Target of $75.
seekingalpha.com Enliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Enliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
prnewswire.com Enliven Therapeutics to Present at Upcoming Investor Conferences BURLINGAME, Calif., Sept. 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and…
seekingalpha.com Enliven Therapeutics: A Clean Active-Site TKI Could Redefine CML Sequencing Enliven Therapeutics is positioned as a late-stage, well-capitalized biotech with $895M cash, funding operations into 2030 and the pivotal ENABLE-2 trial. ELVN-001 targets chronic myeloid leukemia as…- benzinga.com Reported Earlier, Enliven To Present New ELVN-001 Blood Cancer Trial Data At September Medical Meeting Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced…
prnewswire.com Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting BURLINGAME, Calif., Aug. 31, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and…
defenseworld.net BlackRock Inc. Invests $221.25 Million in Enliven Therapeutics, Inc. $ELVN BlackRock Inc. acquired a new stake in shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund…
benzinga.com Enliven's Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says Enliven Therapeutics Inc. (NASDAQ:ELVN) drew an Outperform rating from William Blair on Tuesday as the firm initiated coverage, citing the potential for lead drug candidate ELVN-001 to reshape…
benzinga.com Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says William Blair initiates Enliven Therapeutics (ELVN) with Outperform, highlighting ELVN-001's strong CML trial data & $8.8B market potential.
benzinga.com William Blair Initiates Coverage On Enliven Therapeutics with Outperform Rating William Blair analyst Andy Hsieh initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Outperform rating.- benzinga.com Barclays Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $78 Barclays analyst Etzer Darout initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Overweight rating and announces Price Target of $78.
- benzinga.com Mizuho Maintains Outperform on Enliven Therapeutics, Raises Price Target to $73 Mizuho analyst Salim Syed maintains Enliven Therapeutics (NASDAQ:ELVN) with a Outperform and raises the price target from $62 to $73.
benzinga.com Stifel Maintains Buy on Enliven Therapeutics, Raises Price Target to $82 Stifel analyst Dara Azar maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $80 to $82.- benzinga.com Guggenheim Maintains Buy on Enliven Therapeutics, Lowers Price Target to $78 Guggenheim analyst Michael Schmitz maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and lowers the price target from $80 to $78.
- benzinga.com Goldman Sachs Maintains Buy on Enliven Therapeutics, Raises Price Target to $80 Goldman Sachs analyst Salveen Richter maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $67 to $80.
defenseworld.net Dimensional Fund Advisors LP Raises Holdings in Enliven Therapeutics, Inc. $ELVN Dimensional Fund Advisors LP lifted its position in shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) by 70.9% in the undefined quarter, according to its most recent 13F filing with the SEC. The…
benzinga.com Enliven Therapeutics Q2 EPS $(0.49) Misses $(0.40) Estimate Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.40) by 22.5 percent. This is unchanged from the same period last…
prnewswire.com Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update Announced positive Phase 1 clinical data for ELVN-001 in CML, demonstrating encouraging ELVN-001 efficacy data and a favorable safety and tolerability profile Reached alignment with the FDA on key…
defenseworld.net Enliven Therapeutics, Inc. $ELVN is Avidity Partners Management LP’s 6th Largest Position Avidity Partners Management LP increased its stake in Enliven Therapeutics, Inc. (NASDAQ: ELVN) by 185.1% during the first quarter, according to the company in its most recent 13F filing with the…
benzinga.com Goldman Sachs Maintains Buy on Enliven Therapeutics, Raises Price Target to $67 Goldman Sachs analyst Salveen Richter maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $59 to $67.- benzinga.com HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $64 HC Wainwright & Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $56 to $64.
- benzinga.com Stifel Maintains Buy on Enliven Therapeutics, Raises Price Target to $80 Stifel analyst Dara Azar maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $60 to $80.
- benzinga.com Jones Trading Maintains Buy on Enliven Therapeutics, Raises Price Target to $70 Jones Trading analyst Boris Peaker maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $45 to $70.
fool.com What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130% This Boulder biotech advancing cancer drugs saw a notable insider sale amid strong 1-year stock gains and early clinical progress.
fool.com What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally Orbimed Advisors reported selling 860,123 shares of ELVN on June 22, 2026, generating a transaction value of approximately $39.0 million at an average price of $45.36 per share. This transaction…
prnewswire.com Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares BURLINGAME, Calif., June 15, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and…
gurufocus.com Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants PR Newswire
prnewswire.com Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and…
prnewswire.com Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and…
seekingalpha.com Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia Transcript Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia Transcript
benzinga.com Crude Oil Edges Higher; Driven Brands Posts Upbeat Earnings US stocks rise with Nasdaq up 150 points. Dow up 0.54%, Nasdaq up 0.63%, S&P 500 up 0.26%. Industrials and Enliven Therapeutics lead gains. Dana Inc and Oracle Corp down. Oil up 0.7%, gold down 0.7%.…
benzinga.com Stitch Fix, Intel, KLA And Other Big Stocks Moving Higher On Thursday Stitch Fix (SFIX) reported better-than-expected financial results, causing its shares to jump 15.8%. Other big gainers include Velo3D, Virgin Galactic, and Intel.
benzinga.com Enliven Therapeutics Presents Data From The Phase 1 Enable Clinical Trial Evaluating ELVN-001 In Patients With Previously Treated Chronic Myeloid Leukemia; Notes Encouraging Efficacy Data By 24 Weeks Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today presented…
benzinga.com This Grand Canyon Education Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday Wall Street analysts changed outlook on top names. Check analyst ratings page for upgrades, downgrades, and initiations. See analysts' views on LOPE stock.
benzinga.com Stifel Initiates Coverage On Enliven Therapeutics with Buy Rating, Announces Price Target of $60 Stifel analyst Dara Azar initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Buy rating and announces Price Target of $60.- benzinga.com Enliven Therapeutics To Present Updated Phase 1 ELVN-001 Data In Chronic Myeloid Leukemia At EHA 2026 And Host Investor Webcast On June 11 At 8:30 a.m. ET Enliven will host a webcast conference call on June 11, at 8:30 a.m. ETBURLINGAME, Calif., June 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company)
- benzinga.com Enliven Therapeutics To Present Phase 1 CML Data For ELVN-001, Showing Durable Molecular Response Rates And Favorable Safety In Heavily Pretreated Patients At EHA 2026 Abstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achieving MMR by 24 weeks in mature, heavily pretreated 80 mg QD Phase 1b cohortIn patients who previously…
benzinga.com Goldman Sachs Maintains Buy on Enliven Therapeutics, Raises Price Target to $59 Goldman Sachs analyst Salveen Richter maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $41 to $59.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com CG Oncology, Rich Sparkle Holdings, Liquidia And Other Big Stocks Moving Higher On Friday 
benzinga.com Dow Jumps Over 250 Points; US Initial Jobless Claims Increase - benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Neogen Posts Strong Q2 Earnings, Joins Astronics, Lockheed Martin, Constellation Brands And Other Big Stocks Moving Higher On Thursday